A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Maribavir (Primary) ; Valganciclovir
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Sponsors Shire
- 13 Mar 2017 Status changed from not yet recruiting to recruiting.
- 08 Feb 2017 Planned initiation date changed from 1 Jan 2017 to 1 Mar 2017.
- 10 Oct 2016 New trial record